Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Completed · Phase 3

Conditions studied: Progressive IgA Nephropathy, Proteinuria

In brief

This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.

Key facts

Study ID

NCT02282930

Run by

Mayo Clinic

People needed

20

Starts

2015-03-01

Expected to finish

2018-06-30

Last updated by the study team

2019-06-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Stanford University — Palo Alto, California, United States
• Mayo Clinic Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic in Rochester — Rochester, Minnesota, United States
• Columbia University Medical Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.